Please login to the form below
Incyte
Novartis pulls ahead of Merck in MET-positive lung cancer race
Capmatinib – originally developed by Incyte and licensed to Novartis in 2009 – has been submitted for approval in the US for metastatic MET exon14 skipping-mutated NSCLC, a form of lung cancer
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
to patients and the clinical community around the world,” said Hervé Hoppenot, CEO of Incyte. ... Under the terms of the deal, Incyte is paying MorphoSys $750m upfront, as well as making an equity investment worth $150m in the company.
Incyte claims FDA priority review for bile duct cancer drug
Significant need for new therapies in hard-to-treat cancer type. Incyte’s new drug pemigatinib has been given a priority review for a rare type of bile duct cancer by ... Incyte says cholangiocarcinoma affects between 0.3 – 3.4 people per 100, 000 in
CML LIFE
by INCYTE with support from Open Health PBC. CML Life has been developed using evidence-based methodology, including an extensive literature review focusing on engagement, adherence and side effect management. ... CML LIFE - by INCYTE with support from
Life Effects
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Account Manager
-
£Competitive Salary
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Senior External Communications Lead
-
£Competitive Salary
- Account Director, Healthcare Communications
-
Salary TBC
- Client Services Director - Digital MedComms
-
£60000 - £80000 per annum, Benefits: Pension, healthcare, dedicated training budget, regul
-
Account Director
-
£Competitive Salary
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
-
Scientific Director
-
£60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more
-
Publications director
-
Competitive salary and bonus scheme
-
Account Manager (PR)
-
Great Benefits
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Account director
-
Competitive salary and bonus scheme
-
Account Director, Medical Education
-
Salary TBC
Subscribe to our email news alerts
- J&J gets US backing for vaccine against coronavirus, christened Covid-19
- Genital herpes vaccine candidate heads for human studies
- It started with a miss
- Merck chases Roche with triple-negative breast cancer data for Keytruda
- A market-adapted agile approach to launch excellence
- CRISPR gene-editing in cancer patients is safe, according to new study
- AZ revenues rise, but it says coronavirus could hit 2020
- Seattle Genetics wins FDA priority review for oral HER2 drug
- Eisai agrees to pull obesity drug Belviq after safety alert
- FDA begins speedy review of BMS’ CAR-T liso-cel
- It’s Teenage Kicks for Lucid Group
- 20 for 2020 – Five pharma companies to watch
No results were found
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- 20 for 2020 – Five pharma companies to watch
- As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
- The growing clinical importance of patient-reported outcomes (PROs)
- Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
- The roaring ‘20s and Generation Z
- How a new generation will shape pharma comms this decade...
Quick links
Infographics
